Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/31/15
End: 04/30/17
Due: 04/30/18
Phase: N/A
Priority: Normal
Start: 11/15/21
End: 08/12/24
Due: 08/12/25
Phase: N/A
Priority: Normal
Start: 07/06/20
End: 01/12/24
Due: 01/12/25
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 08/31/14
Due: 08/31/15
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease | NCT02389413 | Vivoryon Therapeutics N.V. | user2@example.com | None | 2015-03-31 | 2017-04-30 | 2018-04-30 | - | - | 2025-07-14 |
| A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD | NCT03919162 | Vivoryon Therapeutics N.V. | user2@example.com | None | 2021-11-15 | 2024-08-12 | 2025-08-12 | - | - | 2025-07-14 |
| A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD | NCT04498650 | Vivoryon Therapeutics N.V. | user2@example.com | None | 2020-07-06 | 2024-01-12 | 2025-01-12 | - | - | 2025-07-14 |
| Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole | NCT02190708 | Vivoryon Therapeutics N.V. | user2@example.com | None | 2014-06-30 | 2014-08-31 | 2015-08-31 | - | - | 2025-07-14 |